Positive interplay between FFAR4/GPR120, DPP-IV inhibition and GLP-1 in beta cell proliferation and glucose homeostasis in obese high fat fed mice

A I Owolabi; R C Corbett; P R Flatt; A M McKillop

doi:10.1016/j.peptides.2024.171218

Positive interplay between FFAR4/GPR120, DPP-IV inhibition and GLP-1 in beta cell proliferation and glucose homeostasis in obese high fat fed mice

A I Owolabi, R C Corbett, P R Flatt, A M McKillop

Research output: Contribution to journal › Article › peer-review

19 Downloads (Pure)

Abstract

G-protein coupled receptor-120 (GPR120; FFAR4) is a free fatty acid receptor, widely researched for its glucoregulatory and insulin release activities. This study aimed to investigate the metabolic advantage of FFAR4/GPR120activation using combination therapy. C57BL/6 mice, fed a High Fat Diet (HFD) for 120 days to induce obesity-diabetes, were subsequently treated with a single daily oral dose of FFAR4/GPR120 agonist Compound A (CpdA) (0.1μmol/kg) alone or in combination with sitagliptin (50mg/kg) for 21 days. After 21-days, glucose homeostasis, islet morphology, plasma hormones and lipids, tissue genes (qPCR) and protein expression (immunocytochemistry) were assessed. Oral administration of CpdA improved glucose tolerance (34% p

Original language	English
Article number	171218
Pages (from-to)	1-26
Number of pages	26
Journal	Peptides
Volume	177
Early online date	13 Apr 2024
DOIs	https://doi.org/10.1016/j.peptides.2024.171218
Publication status	Published online - 13 Apr 2024

Bibliographical note

Publisher Copyright:
© 2024 The Authors

Data Access Statement

Data will be made available on request.

Keywords

Diabetes
Insulin
Incretin
GPR120
FFAR4
GLP-1

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.peptides.2024.171218

1-s2.0-S0196978124000718-mainProof, 594 KBLicence: CC BY

Cite this

@article{1dacb9b0edb14588a028f9b8ed47454e,

title = "Positive interplay between FFAR4/GPR120, DPP-IV inhibition and GLP-1 in beta cell proliferation and glucose homeostasis in obese high fat fed mice",

abstract = "G-protein coupled receptor-120 (GPR120; FFAR4) is a free fatty acid receptor, widely researched for its glucoregulatory and insulin release activities. This study aimed to investigate the metabolic advantage of FFAR4/GPR120activation using combination therapy. C57BL/6 mice, fed a High Fat Diet (HFD) for 120 days to induce obesity-diabetes, were subsequently treated with a single daily oral dose of FFAR4/GPR120 agonist Compound A (CpdA) (0.1μmol/kg) alone or in combination with sitagliptin (50mg/kg) for 21 days. After 21-days, glucose homeostasis, islet morphology, plasma hormones and lipids, tissue genes (qPCR) and protein expression (immunocytochemistry) were assessed. Oral administration of CpdA improved glucose tolerance (34% p",

keywords = "Diabetes, Insulin, Incretin, GPR120, FFAR4, GLP-1",

author = "Owolabi, {A I} and Corbett, {R C} and Flatt, {P R} and McKillop, {A M}",

note = "Publisher Copyright: {\textcopyright} 2024 The Authors",

year = "2024",

month = apr,

day = "13",

doi = "10.1016/j.peptides.2024.171218",

language = "English",

volume = "177",

pages = "1--26",

journal = "Peptides",

issn = "0196-9781",

publisher = "Elsevier",

}

TY - JOUR

T1 - Positive interplay between FFAR4/GPR120, DPP-IV inhibition and GLP-1 in beta cell proliferation and glucose homeostasis in obese high fat fed mice

AU - Owolabi, A I

AU - Corbett, R C

AU - Flatt, P R

AU - McKillop, A M

PY - 2024/4/13

Y1 - 2024/4/13

N2 - G-protein coupled receptor-120 (GPR120; FFAR4) is a free fatty acid receptor, widely researched for its glucoregulatory and insulin release activities. This study aimed to investigate the metabolic advantage of FFAR4/GPR120activation using combination therapy. C57BL/6 mice, fed a High Fat Diet (HFD) for 120 days to induce obesity-diabetes, were subsequently treated with a single daily oral dose of FFAR4/GPR120 agonist Compound A (CpdA) (0.1μmol/kg) alone or in combination with sitagliptin (50mg/kg) for 21 days. After 21-days, glucose homeostasis, islet morphology, plasma hormones and lipids, tissue genes (qPCR) and protein expression (immunocytochemistry) were assessed. Oral administration of CpdA improved glucose tolerance (34% p

AB - G-protein coupled receptor-120 (GPR120; FFAR4) is a free fatty acid receptor, widely researched for its glucoregulatory and insulin release activities. This study aimed to investigate the metabolic advantage of FFAR4/GPR120activation using combination therapy. C57BL/6 mice, fed a High Fat Diet (HFD) for 120 days to induce obesity-diabetes, were subsequently treated with a single daily oral dose of FFAR4/GPR120 agonist Compound A (CpdA) (0.1μmol/kg) alone or in combination with sitagliptin (50mg/kg) for 21 days. After 21-days, glucose homeostasis, islet morphology, plasma hormones and lipids, tissue genes (qPCR) and protein expression (immunocytochemistry) were assessed. Oral administration of CpdA improved glucose tolerance (34% p

KW - Diabetes

KW - Insulin

KW - Incretin

KW - GPR120

KW - FFAR4

KW - GLP-1

UR - http://www.scopus.com/inward/record.url?scp=85191309642&partnerID=8YFLogxK

U2 - 10.1016/j.peptides.2024.171218

DO - 10.1016/j.peptides.2024.171218

M3 - Article

C2 - 38621590

SN - 0196-9781

VL - 177

SP - 1

EP - 26

JO - Peptides

JF - Peptides

M1 - 171218

ER -

Positive interplay between FFAR4/GPR120, DPP-IV inhibition and GLP-1 in beta cell proliferation and glucose homeostasis in obese high fat fed mice

Abstract

Bibliographical note

Data Access Statement

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this